课题基金 / 基金详情

Exploring the Inflammatory Signature of the anti-cancer Smac-mimetic, Birinapant, and the contribution of this signature to Birinapant anti-Tumour activity

Exploring the Inflammatory Signature of the anti-cancer Smac-mimetic, Birinapant, and the contribution of this signature to Birinapant anti-Tumour activity
探索抗癌 Smac 模拟物 Birinapant 的炎症特征,以及该特征对 Birinapant 抗肿瘤活性的贡献
批准号:
nhmrc : GNT1101244
负责人:
Dr Conor Kearney
金额:
$19.23万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2016
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2016-01-01 至 --

项目摘要

项目成果

Dr Conor Kearney的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Programmed cell death (PCD) is an essential process for the removal of cancer cells. Defects in PCD are now known to be a causal factor in cancer initiation and chemotherapeutic resistance. Proteins called IAPs protect cancer cells from PCD, however, inhibitors of IAPs have been developed to kill cancer cells in this respect. Indeed, IAP inhibitors can also promote inflammation, which may improve or hamper their efficacy in killing cancer cells, an issue we now wish to explore and exploit.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapies to Enhance Immunity to Cancer
  • 批准号:
    nhmrc : GNT1122311
  • 项目类别:
    Early Career Fellowships
  • 资助金额:
    $31.88万
  • 财政年份:
    2017
  • 负责人:
    Dr Conor Kearney
  • 依托单位:
海外基金